Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.0
7.8
Journals
Vaccines
Special Issues
Immunization and Immunotherapy against Emerging Infectious Diseases: Current Challenges, Innovative...
share announcement

Immunization and Immunotherapy against Emerging Infectious Diseases: Current Challenges, Innovative Vaccine Development and Vaccine Adjuvant Technologies

A special issue of Vaccines (ISSN 2076-393X).

Deadline for manuscript submissions: closed (31 December 2023) | Viewed by 2308

Special Issue Editors

Dr. Ahmed Mostafa

E-Mail Website
Guest Editor
Center of Scientific Excellence for Influenza Viruses, National Research Centre, 12622 Giza, Egypt
Interests: environmental and medical virology; antiviral research; vaccine development
Special Issues, Collections and Topics in MDPI journals
Dr. Mobarak Abu Mraheil

E-Mail Website
Guest Editor
Giessen Institute for Medical Microbiology, Justus-Liebig University, 35392 Giessen, Germany
Interests: medical microbiology; novel bacterial vaccines development; antimicrobial research; bacterial-based antiviral vaccines

Special Issue Information

Dear Colleagues, 

Newly emerging and reemerging infectious pathogens, especially the unprecedented viral epidemics and pandemics, have threatened animals and humans. Several interlaced and synergistic factors could accelerate the emergence and spread of these life-threatening pathogens in hosts such as animal and/or human populations. Due to the limited antimicrobial options against emerging and reemerging infectious pathogens and the rapid development of drug-resistant strains following uncontrolled implementation of these medications to infected animals, the vaccination and cell-based immunostimulatory therapies remain pivotal options against these infectious pathogens in both animal and human populations. Therefore, in this issue, we are interested in receiving manuscripts for studies with innovative findings in the following topics:

  1. Immunization against emerging infectious diseases;
  2. Immunotherapy against emerging infectious diseases;
  3. Challenges to current vaccination strategies;
  4. Innovative vaccine development (new-generation) technologies;
  5. Novel vaccine adjuvant technologies.

Dr. Ahmed Mostafa
Dr. Mobarak Abu Mraheil
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • viral vaccine
  • bacterial vaccine
  • cell-based antiviral therapy
  • influenza epidemics
  • coronaviruses
  • listeria and salmonella outbreaks

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

15 pages, 4223 KiB  
Article
Immunogenicity and Cross-Protective Efficacy Induced by an Inactivated Recombinant Avian Influenza A/H5N1 (Clade 2.3.4.4b) Vaccine against Co-Circulating Influenza A/H5Nx Viruses
by Sara H. Mahmoud, Ahmed A. Khalil, Noura M. Abo Shama, Marwa F. El Sayed, Reem A. Soliman, Naglaa M. Hagag, Nahed Yehia, Mahmoud M. Naguib, Abdel-Sattar Arafa, Mohamed A. Ali, Mounir M. El-Safty and Ahmed Mostafa
Vaccines 2023, 11(9), 1397; https://0-doi-org.brum.beds.ac.uk/10.3390/vaccines11091397 - 22 Aug 2023
Cited by 2 | Viewed by 2006
Abstract
Controlling avian influenza viruses (AIVs) is mainly based on culling of the infected bird flocks or via the implementation of inactivated vaccines in countries where AIVs are considered to be endemic. Over the last decade, several avian influenza virus subtypes, including highly pathogenic [...] Read more.
Controlling avian influenza viruses (AIVs) is mainly based on culling of the infected bird flocks or via the implementation of inactivated vaccines in countries where AIVs are considered to be endemic. Over the last decade, several avian influenza virus subtypes, including highly pathogenic avian influenza (HPAI) H5N1 clade 2.2.1.2, H5N8 clade 2.3.4.4b and the recent H5N1 clade 2.3.4.4b, have been reported among poultry populations in Egypt. This demanded the utilization of a nationwide routine vaccination program in the poultry sector. Antigenic differences between available avian influenza vaccines and the currently circulating H5Nx strains were reported, calling for an updated vaccine for homogenous strains. In this study, three H5Nx vaccines were generated by utilizing the reverse genetic system: rgH5N1_2.3.4.4, rgH5N8_2.3.4.4 and rgH5N1_2.2.1.2. Further, the immunogenicity and the cross-reactivity of the generated inactivated vaccines were assessed in the chicken model against a panel of homologous and heterologous H5Nx HPAIVs. Interestingly, the rgH5N1_2.3.4.4 induced high immunogenicity in specific-pathogen-free (SPF) chicken and could efficiently protect immunized chickens against challenge infection with HPAIV H5N1_2.3.4.4, H5N8_2.3.4.4 and H5N1_2.2.1.2. In parallel, the rgH5N1_2.2.1.2 could partially protect SPF chickens against infection with HPAIV H5N1_2.3.4.4 and H5N8_2.3.4.4. Conversely, the raised antibodies to rgH5N1_2.3.4.4 could provide full protection against HPAIV H5N1_2.3.4.4 and HPAIV H5N8_2.3.4.4, and partial protection (60%) against HPAIV H5N1_2.2.1.2. Compared to rgH5N8_2.3.4.4 and rgH5N1_2.2.1.2 vaccines, chickens vaccinated with rgH5N1_2.3.4.4 showed lower viral shedding following challenge infection with the predefined HPAIVs. These data emphasize the superior immunogenicity and cross-protective efficacy of the rgH5N1_2.3.4.4 in comparison to rgH5N8_2.3.4.4 and rgH5N1_2.2.1.2. Full article
(This article belongs to the Special Issue Immunization and Immunotherapy against Emerging Infectious Diseases: Current Challenges, Innovative Vaccine Development and Vaccine Adjuvant Technologies)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop